Patrys Limited

Equities

PAB

AU000000PAB9

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 02:10:44 2024-04-26 am EDT			5-day change	1st Jan Change
0.009 ^AUD	0.00%		0.00%	+12.50%

Apr. 10	Patrys Reports 'Positive' Results for Deoxymabs in Autoimmune Vasculitis Treatment	MT
Feb. 23	Patrys Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Patrys secures US patents for antibody technology

April 17, 2023 at 04:46 pm EDT

(via NewsDirect)

Patrys Ltd (ASX:PAB) managing director and CEO Dr James Campbell talks with Proactive’s Elisha Newell about two new patents that advance protection for the company’s antibody technology through to 2039. The first patent, co-filed with Yale University, is the first US patent to be granted specifically for PAT-DX1 and PAT-DX3, while the second covers deoxymabs with nanocarriers — a combination that could provide a powerful new approach for treating cancer. Dr Campbell highlights the growing opportunity in the cancer therapeutics space and says Patrys looks forward to its first-in-human clinical trial for PAT-DX1 next year.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

Latest news about Patrys Limited

Patrys Reports 'Positive' Results for Deoxymabs in Autoimmune Vasculitis Treatment	Apr. 10	MT
Patrys Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 22	CI
Patrys to Begin Production of PAT-DX1 in Q1 2024	Dec. 13	MT
Patrys Limited Announces Retirement of Suzy Jones as Director	23-09-14	CI
Patrys Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-28	CI
Patrys Reports 'Favorable' Results from Pre-Clinical Study of Cancer Therapy	23-05-24	MT
US Patent Office Grants Patrys Two New Deoxymab Patents	23-04-18	MT
Patrys Moves Phase One Trial for Brain Cancer Drug to 2024; Shares Tumble 24%	23-03-31	MT
Patrys Limited Announces New PAT-DX3 Data Demonstrates Synthetic Lethality	23-03-13	CI
Patrys Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-24	CI
Patrys Unit Secures AU$3 Million R&D Tax Refund	23-01-30	MT
Patrys Names Chairman	22-11-16	MT
Patrys Limited Appoints Charmaine Gittleson as the Chairman of the Board of Directors, Effective November 16, 2022	22-11-15	CI
Patrys Limited Announces New Preclinical Data for its Full-Sized IgG Antibody, Pat-DX3	22-10-16	CI
Patrys Limited Announces Appointment of Mr. Stefan Ross as Non-Executive Director	22-08-30	CI
Patrys Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-30	CI
Patrys Limited Announces Update on PAT-DX1 From Engineering Run Meets all Specification Tests	22-08-29	CI
Research Institute Secures Grant Funding to Study Use of Patrys’ Drugs as Breast Cancer Treatment	22-08-26	MT
Patrys Validates Efficacy of Brain Cancer Drug in Preclinical Animal Study	22-08-10	MT
Patrys Limited Announces New Pre-Clinical Data for Its Lead Asset, Pat-Dx1	22-08-09	CI
Patrys Chair to Retire End-August	22-08-07	MT
Patrys Produces Antibody Drug at Commercial Scale	22-07-04	MT
Patrys Limited Announces Successful Completion of Pat-Dx1 Engineering Run	22-07-03	CI
Patrys Identifies New Mechanism of Action for Anti-Cancer Antibody	22-06-14	MT
Patrys Secures Grant Funding to Develop Brain Cancer Drug	22-06-03	MT

Chart Patrys Limited

Duration

Period

More charts

Company Profile

Patrys Limited is an Australia-based company, which is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company's deoxymab platform is based on the deoxymab 3E10 antibody that was identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus. It has developed two humanized forms of deoxymab 3E10, both of which have improved activity over the original deoxymab 3E10 antibody: PAT-DX1, which is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, and PAT-DX3, which is a full-sized Immunoglobulin G antibody. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. Its PAT-DX1- nanoparticles (NP) pipeline involves using its PAT-DX1 to develop a new drug based on the targeted delivery of NP carrying therapeutic payloads to the inside of cancer cells.

Sector

Biotechnology & Medical Research

Calendar

2024-08-21 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PATRYS LIMITED	+12.50%	12.07M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research